GYO18, 2023

Question 1

What is the study question of GYO18?

Answer 1

Pembrolizumab vs placebo to the standard chemotherapy backbone

Question 2

Results of GYO18?

Answer 2

At 12 mo for MMRd, PFS 74% vs 38% favoring pembro

13 vs 8.7 mo for MMRp with 46% lower risk of PD or death

G3+ adverse events were higher in the pembro groups

2y GYO18; 3y RUBY